Alternativas terapêuticas para o tratamento de infecções por Pseudomonas aeruginosa multirresistentes endêmicas no Brasil.

Turano, Helena Gabriela

doi:10.11606/D.42.2012.tde-19042013-103459

Home

Facilities

Master's Dissertation

DOI

https://doi.org/10.11606/D.42.2012.tde-19042013-103459

Document

Master's Dissertation

Author

Turano, Helena Gabriela (Catálogo USP)

Full name

Helena Gabriela Turano

Institute/School/College

Instituto de Ciências Biomédicas

Knowledge Area

Microbiology

Date of Defense

2012-11-29

Published

São Paulo, 2012

Supervisor

Huenuman, Nilton Erbet Lincopan (Catálogo USP)

Committee

Huenuman, Nilton Erbet Lincopan (President)
Castro, Antonio Fernando Pestana de
Garcia, Doroti de Oliveira

Title in Portuguese

Alternativas terapêuticas para o tratamento de infecções por Pseudomonas aeruginosa multirresistentes endêmicas no Brasil.

Keywords in Portuguese

Pseudomonas
Infecção hospitalar
Resistência microbiana às drogas
Sinergismo de drogas

Abstract in Portuguese

Pseudomonas aeruginosa é um dos principais agentes de infecção hospitalar que tem adquirido um caráter endêmico decorrente a sua resistência intrínseca e/ou adquirida aos antibacterianos comercialmente disponíveis. O objetivo do estudo foi avaliar, in vitro, opções terapêuticas baseadas na atividade sinérgica. Dez cepas de P. aeruginosa clonalmente não relacionadas, previamente caracterizadas como produtoras de metalo-beta-lactamase (MbL) do tipo SPM-1, VIM-1 e PA GIM-1, foram avaliadas. O efeito sinérgico foi investigado por Checkerboard e Time-Kill. As combinações [Piperacilina/Tazobactam x Aztreonam] e [Tigeciclina x nanofragmentos de bicamada de brometo de dioctadecildimetilamônio (DDA)] mostraram atividade sinérgica para 90 e 100% das cepas, respectivamente. Os resultados respaldam o uso terapêutico combinado de [Piperacilina/Tazobactam x Aztreonam], contra infecções produzidas por cepas de P. aeruginosa multirresistentes produtoras de MbLs, além disso, [DDA/Tigeciclina] pode constituir a base para consolidar uma nova forma farmacêutica de uso clínico.

Title in English

Alternative therapies for the treatment of infections produced by multidrug-resistant Pseudomonas aeruginosa strains endemic in Brazil.

Keywords in English

Pseudomonas
Drug synergism
Hospital infection
Microbial resistance to drugs

Abstract in English

Pseudomonas aeruginosa is a leading cause of nosocomial infections, which it has acquired an endemic status due to their intrinsic or acquired resistance to antibacterial agents commercially available. The aim of the study was to evaluate in vitro therapeutic options based on the synergistic activity. Ten clonally unrelated strains of P. aeruginosa, previously characterized as metallo-beta-lactamase (MbL) producers (i.e., SPM-1, VIM-1 and PA GIM-1) were evaluated. The synergistic effect was investigated by checkerboard and Time-Kill assays. The combinations [Piperacillin/Tazobactam x Aztreonam] and [Tigecycline x bilayer fragments of dioctadecyldimethylammonium bromide (DDA)] showed synergistic activity for 90 and 100% of the strains, respectively. The results support the use of combined therapy by using [Piperacillin/Tazobactam x Aztreonam] against infections produced by strains of P. aeruginosa producing MbLs, moreover, [DDA / Tigecycline] may be the basis for build a new pharmaceutical form for clinical use.

WARNING - Viewing this document is conditioned on your acceptance of the following terms of use:
This document is only for private use for research and teaching activities. Reproduction for commercial use is forbidden. This rights cover the whole data about this document as well as its contents. Any uses or copies of this document in whole or in part must include the author's name.

HelenaGabrielaTurano_Mestrado_Corr.pdf (2.93 Mbytes)

HelenaGabrielaTurano_Mestrado_P_Corr.pdf (885.65 Kbytes)

Publishing Date

2013-05-28

Derived works

WARNING: Learn what derived works are clicking here.